Conference Program

Conference Program

10:30 - 10:50

Welcome Address

Plenary Hall
Plenary Hall

Keynote lecture: CAR T CELLS – A ROAD TRIP TO TUMOR ELIMINATION
Stan Riddell,
Fred Hutchinson Cancer Research Center, USA

CAR T CELL THERAPIES IN LYMPHOMA: CURRENT STATUS OF IND-APPROVED STUDIES IN CHINA
Yuqin Song,
Peking University Cancer Hospital, China

MULTIPLE GENOME EDITING IN T CELLS FOR CANCER IMMUNOTHERAPY
Chiara Bonini,
San Raffaele University, Italy

TBC
Michal Besser,
Tel Aviv University, Israel

Discussion

Plenary Hall

TBC
Hans Stauss,
University College London, UK

L1CAM-SPECIFIC CAR T CELL THERAPY FOR CHILDHOOD NEUROBLASTOMA
Annette Künkele,
Charité,Germany

ENHANCEMENT OF CAR T CELL FUNCTION WITH A CONSTITUTIVELY ACTIVE IL-7 RECEPTOR
Bilal Omer,
Baylor College of Medicine, USA

TBC

Discussion

16:10 – 18:00

CAR/TCR design

Plenary Hall

T CELL RECEPTOR GENE THERAPY FOR ‘PUBLIC’ NEOANTIGENS DERIVED FROM COMMON DRIVER ONCOGENES
Chris Klebanoff,
Memorial Sloan Kettering Cancer Center, USA

NEOANTIGEN-SPECIFIC T-CELL RECEPTORS AS PERSONALIZED TOOLS IN THE TREATMENT OF CANCER
Angela Krackhard,
Klinikum rechts der Isar, Technical University of Munich, Germany

PRIMARY STRUCTURE INFLUENCE ON THE EXPRESSION AND FUNCTION OF TCRS, CARS AND CSRS FOR T-CELL IMMUNOTHERAPY
Cyrille Cohen,
Bar-Ilan University, Israel

TBC

Discussion

Plenary Hall

DUAL TARGETING OF CANCER AND SUPPRESSIVE MYELOID CELLS BY TCR-ENGINEERED INKT CELLS
Paolo Dellabona,
San Raffaele Scientific Institute, Italy

TBC

Discussion

11:05 – 12:50

Universal donor cells

Plenary Hall

Keynote lecture: FRATRICIDE AS AN ENABLER OF UNIVERSAL T CELL THERAPY
“WAS MICH NICHT UMBRINGT, MACHT MICH STÄRKER``
Malcolm Brenner,
Houston Methodist Hospital, USA

INCREASING THE SAFETY OF CAR TECHNOLOGY: GATED TARGETING WITH MODULAR CARS
Michael Bachmann,
University Hospital Carl Gustav Carus Dresden, Germany

TBC
Waseem Qasim,
University College London,UK

TBC

Discussion

Plenary Hall

TBC
Dirk Busch,
Technical University of Munich, Germany

T CELL THERAPY FOR VIRUSES
Ann Leen,
Baylor College of Medicine, USA

TBC
Adi Barzel,
Tel-Aviv University, Israel

TBC

Discussion

Plenary Hall

TBC

ADOPTIVE TRANSFER OF VIRUS-SPECIFIC T CELLS IN THE IMMUNOCOMPROMISED HOST
Tobias Feuchtinger,
Ludwig-Maximilians-University, Germany

SIGNALING AND CYTOKINE ENGINEERING OF CAR-T CELLS
Gianpietro Dotti,
University of North Carolina Lineberger Comprehensive Cancer Center, USA

TBC

Discussion

Plenary Hall

PIGGYBAC TRANSPOSON-MEDIATED CAR-T CELLS: A PROMISING AND REALISTIC APPROACH FOR CLINICAL APPLICATION
Shigeki Yagyu,
Kyoto Prefectural University of Medicine, Kyoto, Japan

NOVEL TARGETS AND TECHNOLOGIES FOR CAR T-CELL THERAPY
Michael Hudecek,
Hospital of the University of Würzburg, Germany

TBC

Discussion

Plenary Hall

Keynote lecture
Carl June,
Parker Institute Cancer Immunotherapy; University of Pennsylvania USA

TANDOM CD19-CD20 CAR T TREATMENT IN R/RNHL
Weidong Han,
Chinese PLA General Hospital, China

CARS AND TRUCKS AND THE NEXT GENERATION CAR T CELLS
Hinrich Abken,
Regensburg Center for Interventional Immunotherpay, Germany

Panel discussion

12:20 - 12:30

Closing Address

Plenary Hall